C3: Potential Drug Target and Biomarker for Diseases (G718)

Target Name: C3

NCBI ID: G718

Content of Review Report on C3 Target / Biomarker

C3: Potential Drug Target and Biomarker for Diseases

C3 (Acylation stimulating protein) is a protein that has been shown to have a variety of roles in cellular signaling pathways, including modulating the immune response and influencing cellular processes such as cell division and metabolism. C3 is also a potential drug target and biomarker for several diseases.

The immune response is a critical mechanism that helps the body defend against harmful pathogens and diseases. C3 plays a key role in this process by regulating the activation and function of natural killer cells, which are a crucial part of the immune system. C3 helps to ensure that natural killer cells are properly regulated and that they are able to effectively recognize and destroy infected or mutated cells.

C3 is also involved in the regulation of cell division and cell growth. It has been shown to play a role in the control of cell proliferation and in the regulation of cell cycle progression. This protein has been shown to promote the G1 phase of the cell cycle and to inhibit the S phase. This means that C3 helps to ensure that cells are able to properly divide and grow, and that they are able to maintain a stable cell cycle.

C3 has also been shown to be involved in the regulation of cell adhesion. This protein helps to ensure that cells are able to stick together and form tissues, and it has been shown to play a role in the development and maintenance of tissues such as tissues and organs.

In addition to its role in immune and cellular signaling pathways, C3 has also been shown to be a potential drug target and biomarker for several diseases. For example, C3 has been shown to be involved in the development and progression of several types of cancer, including breast cancer and ovarian cancer. This makes it an attractive target for cancer therapies that aim to inhibit the activity of this protein.

Another potential application of C3 as a drug target is its role in the regulation of inflammation. C3 has been shown to play a role in the regulation of inflammatory responses and has been shown to help to control the production of pro-inflammatory cytokines. This makes it an attractive target for therapies that aim to reduce inflammation and improve overall health.

In addition to its potential as a drug target and biomarker, C3 is also a potential biomarker for several diseases. For example, C3 has been shown to be involved in the regulation of the immune response and has been shown to be decreased in individuals with certain diseases. This makes it an attractive candidate for use as a biomarker for diseases such as cancer and autoimmune disorders.

Overall, C3 is a protein that has a variety of roles in cellular signaling pathways and has been shown to be involved in the development and progression of several diseases. As a result, it is an attractive target for drug development and has the potential to be a valuable biomarker for the diagnosis and treatment of a variety of diseases.

Protein Name: Complement C3

Functions: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates

The "C3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets